KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Net Cash Flow (2016 - 2025)

Thermo Fisher Scientific's Net Cash Flow history spans 17 years, with the latest figure at $7.9 billion for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 2311.8% year-over-year to $7.9 billion, compared with a TTM value of $5.6 billion through Dec 2025, up 240.49%, and an annual FY2025 reading of $5.6 billion, up 240.49% over the prior year.
  • Net Cash Flow for Q4 2025 was $7.9 billion at Thermo Fisher Scientific, up from -$2.5 billion in the prior quarter.
  • The five-year high for Net Cash Flow was $7.9 billion in Q4 2025, with the low at -$7.8 billion in Q4 2021.
  • Average Net Cash Flow over 5 years is -$30.3 million, with a median of -$131.0 million recorded in 2024.
  • Year-over-year, Net Cash Flow plummeted 781.12% in 2021 and then skyrocketed 2311.8% in 2025.
  • Tracing TMO's Net Cash Flow over 5 years: stood at -$7.8 billion in 2021, then soared by 168.91% to $5.4 billion in 2022, then tumbled by 64.15% to $1.9 billion in 2023, then tumbled by 118.55% to -$356.0 million in 2024, then skyrocketed by 2311.8% to $7.9 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Net Cash Flow are $7.9 billion (Q4 2025), -$2.5 billion (Q3 2025), and $120.0 million (Q2 2025).